Osteonecrosis of the jaw and bisphosphonates: A comparison with white phosphorus, radium, and osteopetrosis

References

• Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New Eng J Med 1998; 339: 947–952
   PubMed Web of Science ®Google Scholar
• Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14: 617–630
   PubMed Web of Science ®Google Scholar
• Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clinical Oncology 2003; 21: 4253–4254
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced asvascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117
   PubMed Web of Science ®Google Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575
   PubMed Web of Science ®Google Scholar
• Bamais A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphophonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–8587
   PubMed Web of Science ®Google Scholar
• Lai K-A, Shen W-J, Yang C-Y, Shao C-J, Hsu J-T, Lin R-M. The use of alendronate to prevent early collapse of the femoral head in patients with nontruamatic osteonecrosis. J Bone Joint Surg 2005; 87A: 2155–2159
   Web of Science ®Google Scholar
• Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaw associated with cancer chemotherapy. J Oral Maxillfac Surg 2003; 61: 1104–1107
   PubMed Web of Science ®Google Scholar
• Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillfac Surg 2003; 61: 1238–1239
   PubMed Web of Science ®Google Scholar
• Emsley J. The 13^th element: The sordid tale of murder, fire and phosphorus. John Wiley & Sons Inc, New York 2000
   Google Scholar
• Gordon B. Phossy jaw and the French match makers: Occupational health and women in the Third Republic. Garland Publishing Inc, New York 1989
   Google Scholar
• Schirmer I, Peters H, Reichart R, Durkop H. Bisphoshonate und Oseonekrosen im Kieferbereich. Mund Kifer Gesichts Chir 2005; 9: 239–245
   PubMedGoogle Scholar
• Schwartz H. Osteonecrosis and bisphosphonates: Correlation versus causation. J Oral Maxillofac Surg 2004; 62: 763–764
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4095T2.htm, Young D. ONJ reported in bisphosphonate-treated patients. In: Oncologic Drugs Advisory Committee, volume II, Food and Drug Administration Center for Drug Evaluation and Research hearings, March 4, 2005:231–237.
   Google Scholar
• Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation by caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacologic classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131–140
   PubMed Web of Science ®Google Scholar
• Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon MP, Benford HL, Croucher PI, Shipman C, Fleisch HA. The pharmacology of bisphosphonates and new insights into their mechanisms of actions. J Bone Miner Res 1999; 14(Suppl 2)53–65
   PubMedGoogle Scholar
• MacGowan JR, Pringle J, Morris VH, Stamp TC. Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. Skeletal Radiol 2000; 29: 279–282
   PubMed Web of Science ®Google Scholar
• Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate. Arthritis Rheum 2001; 44: 2201–2210
   PubMed Web of Science ®Google Scholar
• Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reska AA. Alendronate mechanism of action: geranylgeraniol, an intermendiate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Nat Acad Sci 1999; 96: 133–138
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231–241
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004; 4: 711–719
   PubMed Web of Science ®Google Scholar
• Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramseier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45: 3721–3738
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, Atkins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–2105
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: Differences in interaction with hydroxyapatite. Bone 2006; 38: 617–627
   PubMed Web of Science ®Google Scholar
• Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18: 75–85
   PubMed Web of Science ®Google Scholar
• Cremers SCLM, Goonaseelan P, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimization of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44: 551–570
   PubMed Web of Science ®Google Scholar
• Favus MJ, Vokes TJ. Paget disease and other dysplasias of bone. Harrison's principles of internal medicine16th, DL Kasper, AS Fauchi, E Braunwald, S Hauser, DL Longo, JL Jameson. McGraw-Hill, New York 2005; 2279–2282
   Google Scholar
• Van der Pluijm G, Vloedgraven H, van Beek E, van der WeePals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705
   PubMed Web of Science ®Google Scholar
• Green JR. Bisphosphonates: Preclinical review. Oncologist 2004; 9(Suppl 4)3–13
   PubMed Web of Science ®Google Scholar
• Felton JS. Phosphorus necrosis – A classical occupational disease. Am J Industrial Medicine 1982; 3: 77–120
   PubMedGoogle Scholar
• Myers ML, McGlothlin JD. Matchmakers' “phossy jaw” eradicated. Am Ind Hyg Assoc J 1996; 57: 330–332
   PubMedGoogle Scholar
• http://cdl.library.cornell.edu/cgi-bin/moa/pageviewer?root=%2Fmoa%2Fmanu%2Fmanu0001%2F&tif=00274.TIF&cite=http%3A%2F%2Fcdl.library.cornell.edu%2Fcgi-bin%2Fmoa%2Fmoa-cgi%3Fnotisid%3DABS1821-0001-523&coll=moa&frames=1&view=50, Anonymous. The manufacture of Lucifer matches. Manufacturer and Builder Sept. 1869, Vol. 1 (#9):268–269.
   Google Scholar
• Heimann H. Chronic phosphorus poisoning. J Indust Hyg Toxicol 1946; 28: 142–150
   PubMedGoogle Scholar
• Hamilton A. Chronic phosphorus poisoning. Diseases of occupation and industrial hygiene, G Kober, WK Hanson. P. Blackstones & Sons & Co, Philadelphia 1916; 145–152
   Google Scholar
• Henderson Y, Haggard HW. Noxious gases and the priciples of respiration influencing their action. American Chemical Society Monograph Series No. 25. The Chemical Catalog Company, 1927, New York, 182–184
   Google Scholar
• Hamilton A. Exploring the dangerous trades. Little, Brown & Co, Boston 1943
   Google Scholar
• Boyd LJ. Phosphorus. The Hahnemannian Monthly. 1924; 59: 129–138
   Google Scholar
• Wakefield BG. Phosphorous necrosis of the mandible: report of two cases. J Oral Surg 1948; 6: 263–268
   PubMedGoogle Scholar
• Adams CO, Sarnat B. Effects of yellow phosphorus and arsenic trioxide on growing bones and growing teeth. Arch Pathology 1940; 30: 1192–1202
   Google Scholar
• Fleming RBL, Miller JW, Swayne VR, Jr. Some recent observations on phosphorus toxicology. J Indust Hygeine 1942; 24: 154–158
   Google Scholar
• Wegner G. Der Einfluss des Phosphors auf den Organismus. Virchows Arch f. path Anat 1872; 55: 11–45
   Google Scholar
• Hughes JPW, Baron R, Buckland DH, Cooke MA, Craig JD, Duffield DF, Grosart AW, Parker PW, Porter A. Phosphorus necrosis of the jaw: a present-day study. Brit J Industr Med 1962; 19: 83–99
   PubMedGoogle Scholar
• http://www.atsdr.cdc.gov/toxprofiles/tp103.pdf, Agency for Toxic Substance and Disease Registry. Toxicological profile for white phosphorus, US Department of Health and Human Services, September 1997.
   Google Scholar
• Stewart E. Radium poisoning: Industrial poisoning from radioactive substances. Monthly Labor Rev June, 1929; 28: 20–61
   Google Scholar
• St George AV, Gettler AO, Muller RH. Radioactive substances in a body five years after death. Arch Pathol 1929; 7: 397–405
   Google Scholar
• Martland HS, Conlon P, Knef JP. Some unrecognized dangers in the use and handling of radioactive substances. J Amer Med Assoc 1925; 85: 1769–1776
   Google Scholar
• Sharpe WD. The New Jersey radium dial painters: A classic in occupational carcinogenesis. Bull Hist Med 1979; 52: 560–570
   Web of Science ®Google Scholar
• Cloutier RJ. Florence Kelley and the radium dial painters. Health Physics 1980; 39: 711–716
   PubMed Web of Science ®Google Scholar
• Aub JC, Evans RD, Hempelmann LH, Martland HS. The late effects of internally-deposited radioactive materials in man. Medicine 1952; 31: 221–329
   PubMed Web of Science ®Google Scholar
• Marx RE. Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41: 283–288
   PubMed Web of Science ®Google Scholar
• Committee on the Biological Effects of Ionizing Radiations. Health risks of radon and other internally deposited alpha-emitters: BIER IV. National Research Council, Wahsington, DC 1988
   Google Scholar
• Lacassagne A. Un nouvel accident professionnel des manipulateurs de corps radioactifs: la necrose des maxillaries. Paris Medical 1926; 16: 132–135
   Google Scholar
• Gettler AO, Norrris C. Poisoning from drinking radium water. J Amer Med Assoc 1933; 100: 400–402
   Google Scholar
• Macklis RM. The great radium scandal. Scientific American August, 1993; 94–99
   PubMed Web of Science ®Google Scholar
• Spiess H. Peteosthor – a medical disaster due to radium-224. Radiat Envion Biophys 2002; 41: 163–172
   PubMed Web of Science ®Google Scholar
• Lloyd RD, Taylor GN, Miller SC, Bruenger FW, Jee WSS. Review of 239Pu and 226Ra effects in beagles. Health Phys 2001; 81: 691–697
   PubMed Web of Science ®Google Scholar
• Robins MW. 224Ra-induced osteopenia in male CBA mice. Calcif Tissue Int 2000; 46: 94–100
   Google Scholar
• Whyte MP. Osteopetrosis. Connective tissue and its heritable disorders2nd, RM Royce, B Steinmann. Wiley-Liss, New York 2002; 789–807
   Google Scholar
• Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. New Eng J Med 2004; 351: 2839–2849
   PubMed Web of Science ®Google Scholar
• Benichou OD, Laredo JD, de Vernejoul MC. Type II autosomal dominant osteopetrosis (Albners-Schonberg disease): Clinical and radiological manifestations in 42 patients. Bone 2000; 26: 87–93
   PubMed Web of Science ®Google Scholar
• El-Tawil T, Stoker DJ. Benign osteopetrosis: A review of 42 cases showing two different patterns. Skeletal Radiol 1993; 22: 587–593
   PubMed Web of Science ®Google Scholar
• Kaczmarczyk-Sedlak I. The effect of pamidronate on mechanical properties, growth and structural changes in rat bones. Acta Poloniae Pharmaceutica 1995; 52: 509–513
   PubMedGoogle Scholar
• Reynolds JJ, Murphy H, Muhlbauer RC, Fleisch H. Inhibition by diphosphonates in mice and comparison with gray-lethal osteopetrosis. Calcif Tiss Res 1973; 12: 59–71
   PubMedGoogle Scholar
• Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. New Eng J Med 2003; 349: 457–463
   PubMed Web of Science ®Google Scholar
• Steiner, Gould AR, Means WR. Osteomyelitis of the mandible associated with osteopetrosis. J Oral Maxillofac Surg 1963; 41: 395–405
   Google Scholar
• Crockett DM, Stanley RB, Lubka R. Osteomyelitis of the maxilla in a patient with osteopetrosis (Albers-Schonberg disease). Otolaryngology-Head Neck Surg 1986; 95: 117–121
   PubMed Web of Science ®Google Scholar
• Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236–1238
   PubMed Web of Science ®Google Scholar
• Gelb BD, Brömme D, Desnick RJ. Pycnodysostosis: Cathepsin K deficiency. The metabolic and molecular basis of inherited disease8th, CR Scriver, AL Beaudet, WS Sly, D Valle. McGraw-Hill, New York 2001; 3453–3468
   Google Scholar
• Bouquot JE, McMahon RE. Neuropathic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 2000; 58: 1003–1020
   PubMed Web of Science ®Google Scholar
• Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006; 73: 7–9
   PubMed Web of Science ®Google Scholar
• Kennon R, Hallam JW. Modern phophorus caries and necrosis. Br Dental 1944; 76: 321–330
   Google Scholar
• Ward EF. Phosphorus necrosis in the manufacture of fireworks. J Indust Hyg 1928; 10: 314–350
   Google Scholar
• Dearden WF. Fragilitas ossium amongst workers in Lucifer match factories. Brit Med J 1899; 2: 270–271
   PubMedGoogle Scholar
• Stebbings JH. Health risks from radium in workplaces: An unfinished story. Occupational Medicine 2001; 16: 259–270
   Web of Science ®Google Scholar
• Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Rev 1998; 47: 237–240
   Google Scholar
• Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055–1061
   PubMed Web of Science ®Google Scholar
• Whalen JP, O'Donohue N, Krook L, Nunez EA. Pathogenesis of abnormal remodeling of bones: Effects of yellow phosphorus in the growing bone. Anat Rec 1973; 177: 15–22
   PubMedGoogle Scholar
• Jee WSS, Bartley MH, Dockum NL, Yee J, Kenner GH. Vascular changes in bones following bone-seeking radionuclides. Delayed effects of bone-seeking radionuclides, CW Mays, WSS Jee, RD Lloyd. University of Utah Press, Salt Lake CityUT 1969
   Google Scholar
• Doty SB, Yates CW, Lotz WE, Kisecleski W, Talmage RV. Effect of short term alpha irradiation on parathyroid activity and osteoclast numbers. Proc Soc Exp Biol Med 1965; 119: 77–81
   PubMed Web of Science ®Google Scholar
• Scheven BAA, Burger EH, Kawilarang-de Haas EWM, Wassenaar AM, Nijweide PJ. Effects of ionizing irradiation on formation and resorbing activity of osteoclasts in vitro. Lab Invest 1985; 53: 72–79
   PubMed Web of Science ®Google Scholar
• Devogelaer J-P. Treatment of bone diseases with bisphosphonates. Curr Opinion Rheumatology 2000; 12: 331–335
   PubMed Web of Science ®Google Scholar
• Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10: 52–62
   PubMed Web of Science ®Google Scholar
• Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53: 283–288
   PubMed Web of Science ®Google Scholar
• Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003; 32: 45–55
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 2003; 32: 120–126
   PubMed Web of Science ®Google Scholar
• Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: The Fracture Intervention Trial. Mayo Clin Proc 2005; 80: 343–349
   PubMed Web of Science ®Google Scholar
• Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrin Metab 1994; 78: 968–972
   PubMed Web of Science ®Google Scholar
• Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000; 15: 754–762
   PubMed Web of Science ®Google Scholar
• Lenz J-H, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KKH. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J CranioMaxillofac Surg 2005; 33: 395–403
   PubMed Web of Science ®Google Scholar
• Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of iv bisposphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842–848
   PubMed Web of Science ®Google Scholar
• Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. New Eng J Med 2005; 353: 99–100
   PubMed Web of Science ®Google Scholar
• Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185–194
   PubMed Web of Science ®Google Scholar
• Abu-Id MH, Acil Y, Gottschalk J, Kreusch T. Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund-, Kiefer- und Gesichtschir 2006; 10: 73–81
   PubMedGoogle Scholar
• Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000; 88: 1082–1090
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen B-L, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003; 98: 1735–1744
   PubMed Web of Science ®Google Scholar
• Body J-J, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff WW, Gorbunova VA, Budde M, Bergstrom B. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–1405
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlick M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other sold tumors: A phase III, double-blind, randomized trial – The Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003; 21: 3150–3157
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314–3321
   PubMed Web of Science ®Google Scholar
• Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal Intervention Cohort Study. A randomized, controlled trial. Ann Int Med 1999; 131: 935–942
   PubMed Web of Science ®Google Scholar
• McClung MR, Guesens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Eng J Med 2001; 344: 333–340
   PubMed Web of Science ®Google Scholar
• Glueck CJ, McMahon RE, Bouquot J, Stroop D, Tracy T, Wang P, Rabinovich B. Thrombofilia, hypofibrinolysis, and alveolar osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Radiol Endod 1996; 81: 557–566
   PubMed Web of Science ®Google Scholar
• McMahon RE, Bouquot JE, Glueck CJ, Spolnik KJ, Adams WR. Osteonecrosis: A multifactorial etiology. J Oral Maxillofac Surg 2004; 62: 904–905
   PubMed Web of Science ®Google Scholar
• Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90: 1897–1899
   PubMed Web of Science ®Google Scholar
• Whyte MP. The long and short of bone therapy. New Eng J Med 2006; 354: 860–863
   PubMed Web of Science ®Google Scholar
• Kaczmarczyk-Sedlak I. The effect of pamidronate on mechanical properties, growth and structural changes in rat bones. Acta Poloniae Pharmaceutica 1995; 52: 509–513
   PubMedGoogle Scholar
• Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 621–625
   PubMedGoogle Scholar
• Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294–1301
   PubMed Web of Science ®Google Scholar
• Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61: 31–33
   PubMed Web of Science ®Google Scholar
• Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19: 1779–1786
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen I-W, Duggan DE. Effects of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Disp 1992; 20: 473–478
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer J-P, Kaufman J-M, Jaeger P, Body J-J, Mieunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Eng J Med 2002; 346: 653–661
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane Review). The Cochrane Library. 2005, Accession Number: CD003474.
   Google Scholar
• Lugassy G. Safety and convenience of a 15-minute infusion of zoledronic acid: Not so safe. Oncologist 2005; 10: 309–310
   PubMed Web of Science ®Google Scholar
• Parles K. Regarding Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10: 304–305
   PubMed Web of Science ®Google Scholar
• Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance – lack of vigilance, lack of trust. JAMA 2004; 292: 2647–2650
   PubMed Web of Science ®Google Scholar
• Gibbs SDJ, O'Grady J, Seymour JF, Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Australia 2005; 21: 549–550
   Google Scholar
• Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006; 81: 73–75
   PubMed Web of Science ®Google Scholar
• Najm SA, Lysitsa S, Carrel J-P, Lesclous P, Lombardi T, Samson. Osteonecrose des maxillaires chez des patients traites par bisphosphonates. Presse Med 2005; 34: 1073–1077
   PubMedGoogle Scholar
• Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphophonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc 2005; 136: 1675–1681
   PubMed Web of Science ®Google Scholar
• Farrugia M, Summerlin D-J, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116: 115–120
   PubMed Web of Science ®Google Scholar
• Carter G, Goss ANN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Australia 2005; 182: 413–415
   PubMed Web of Science ®Google Scholar
• Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. New Eng J Med 2005; 353: 100–101
   Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bishosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527–534
   PubMed Web of Science ®Google Scholar
• Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Oral Oncology 2006; 42: 327–329
   PubMed Web of Science ®Google Scholar
• Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Australia 2005; 182: 417–418
   PubMed Web of Science ®Google Scholar
• Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83–93
   PubMed Web of Science ®Google Scholar
• Mullner R. Deadly glow: The radium dial worker tragedy. American Public Health Association, Washington, DC 1999
   Google Scholar
• Rowland RE. Radium in humans: a review of US studies. Argonne National Laboratory, Argonne, Illinois 1994
   Google Scholar
• Clark C. Radium girls: Women and industrial health reform, 1910–1935. University of North Carolina Press, Chapel Hill 1997
   Google Scholar
• http://www.atsdr.cdc.gov/toxprofiles/tp144.pdf, Agency for Toxic Substance and Disease Registry: Toxicological profile for radium, US Department of Health and Human Services, December 1990.
   Google Scholar
• Castle WB, Drinker KR, Drinker CK. Necrosis of the jaw in workers employed in applying a luminous paint containing radium. J Indust Hyg 1925; 7: 371–382
   Google Scholar
• Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis Int 1998; 8: 97–103
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Nat Cancer Int 2004; 96: 879–882
   PubMed Web of Science ®Google Scholar